Wyoming Opts Out of Federal Medical Cannabis Rescheduling

State Invokes Rarely-Used CSA Opt-Out Provision

Wyoming invoked Section 903 of the Controlled Substances Act, a provision allowing states to maintain stricter controlled-substance schedules than federal law. The state's filing, submitted by Wyoming Attorney General Bridget Hill, argues that the DEA's rescheduling to Schedule III conflicts with Wyoming Statute § 35-7-1014, which prohibits any form of cannabis legalization for medical or recreational use.

Section 903 has been invoked fewer than a dozen times since the CSA's enactment in 1970, primarily for synthetic opioids and precursor chemicals. This marks the first application to cannabis scheduling. States must demonstrate that federal rescheduling would "undermine the effective enforcement" of state drug laws.

Legal and Operational Implications for Wyoming Patients

The opt-out means Wyoming residents can't access medical cannabis under the federal Schedule III framework, even with a physician recommendation. Federal rescheduling, finalized by the DEA in April 2026, allows physicians in participating states to recommend cannabis for nine qualifying conditions without violating the CSA. Wyoming's rejection preserves criminal penalties for possession, cultivation, and distribution.

Wyoming law currently classifies cannabis as a Schedule I controlled substance. Penalties? Six months to five years for first-offense possession of more than three ounces. The state has no medical cannabis program and rejected ballot initiatives in 2022 and 2024 by margins exceeding 60%.

Patients who travel across state lines to Colorado or Montana for medical cannabis remain subject to Wyoming prosecution upon return. Interstate transport of Schedule III controlled substances without a valid prescription remains a federal felony under 21 U.S.C. § 841.

Federal Response and Precedent Watch

The DEA has 90 days to accept or challenge Wyoming's opt-out filing under CSA procedural rules. If accepted, Wyoming becomes a carve-out jurisdiction where federal Schedule III cannabis provisions don't apply. If challenged, the dispute moves to the U.S. Court of Appeals for the Tenth Circuit, which has jurisdiction over Wyoming.

A successful opt-out could encourage similar filings from Idaho, Nebraska, and Kansas—three states with Republican-controlled legislatures and no medical cannabis programs. Idaho Attorney General Raúl Labrador told the Idaho Statesman in June that his office was "evaluating all options" to preserve the state's cannabis prohibition.

For full background on the federal rescheduling process, see the CannIntel topic hub on Federal Cannabis Rescheduling.

The next procedural deadline is October 7, 2026, when the DEA must either publish a notice of acceptance in the Federal Register or file a formal objection. Wyoming's filing includes 47 pages of supporting documentation—legislative history, public-health data, and citations to state court precedent. CannIntel has requested a copy of the full filing under FOIA.